Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybrid, High-dose Dual, and Bismuth Quadruple Therapies for H. pylori
NCT03779074Phase 3
Key facts
- Status
- Completed
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Countries
- 1
- Sponsor
- Kaohsiung Veterans General Hospital
- Modality
- Small Molecules
- Conditions
- Helicobacter pylori infection
01
Overview
Phase 3, randomised, open-label trial of amoxicillin, rabeprazole, clarithromycin and metronidazole in Helicobacter pylori infection, sponsored by Kaohsiung Veterans General Hospital. Started Sep 2018; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection.
Beyond the preview
Go deeper on NCT03779074.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779074.